HC Wainwright & Co. maintains Buy rating on Atrium Therapeutics, $20 price target

HC Wainwright & Co. maintained their Buy rating on Atrium Therapeutics's stock with a price target of $20.00.

The price target implies an upside of 140.4% from the Oct 27 close of $8.32.

Key takeaways from the analyst note

Promising Clinical Development: Atrium Therapeutics is making significant progress in its clinical trials, particularly with the Corventis study for ATR 1072 targeting PRKAG2 syndrome, which is set to provide initial human proof-of-concept data in the second half of 2027. This advancement supports investor confidence in the company's potential for success in delivering RNA-based therapeutics to heart tissue.

Strong Financial Backing: The recent $50 million financing enhances Atrium's cash runway until 2028, ensuring that the company can fund its ongoing and future clinical programs, including the anticipated IND filing for ATR 1086 targeting PLN cardiomyopathy. This financial stability is crucial for sustaining development efforts and mitigating risks, reinforcing the Buy rating.

Explore more price target data and ratings for Atrium Therapeutics on the Forecasts tab.